Assessment of individual cognitive changes after deep brain stimulation surgery in Parkinson's disease using the Neuropsychological Test Battery Vienna short version.
Long-term therapy of Parkinson's disease with L‑DOPA is associated with a high risk of developing motor fluctuations and dyskinesia. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) can improve these motor complications. Although the positive effect on motor symptoms has been proven, postoperative cognitive decline has been documented. To tackle the impact of DBS on cognition, 18 DBS patients were compared to 25 best medically treated Parkinson's patients, 24 patients with mild cognitive impairment (MCI) and 12 healthy controls using the Neuropsychological Test Battery Vienna short version (NTBV-short) for cognitive outcome 12 months after the first examination. Reliable change index methodology was used. Roughly 10% of DBS patients showed cognitive decline mainly affecting the domains attention and executive functioning (phonemic fluency). Further research is needed to identify the mechanisms that lead to improvement or deterioration of cognitive functions in individual cases.
Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.
Thomas
T
Foki
Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.
Daniela
D
Hitzl
Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.|Department of Neurology, Wilhelminenspital Wien, Vienna, Austria.
Walter
W
Pirker
Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Klaus
K
Novak
Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.
Gisela
G
Pusswald
Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.
Eduard
E
Auff
Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria. johann.lehrner@meduniwien.ac.at.
Johann
http://orcid.org/0000-0001-8270-9272
J
Lehrner
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001288:Attention / Q000502:physiology; D060825:Cognitive Dysfunction / Q000175:diagnosis* / Q000503:physiopathology; D015331:Cohort Studies; D046690:Deep Brain Stimulation / Q000009:adverse effects*; D056344:Executive Function / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests / Q000706:statistics & numerical data*; D010300:Parkinson Disease / Q000503:physiopathology / Q000601:surgery*; D011446:Prospective Studies; D013064:Speech Disorders / Q000175:diagnosis / Q000503:physiopathology; D020531:Subthalamic Nucleus / Q000503:physiopathology
D000978:Antiparkinson Agents
Cognition; Deep brain stimulation; MCI; Parkinson’s disease; Subthalamic nucleus